Article information
En múltiples modelos experimentales, la angiotensina II ha demostrado ser la piedra angular de la progresión renal en las nefropatías proteinúricas, por su papel sobre la hemodinámica glomerular (aumenta la resistencia de la arteriola eferente) pero también por su capacidad proinflamatoria y profibrótica al estimular la síntesis de TNFa, Il-6, y citoquinas como MCP-1 e IP-101. En los últimos años también se ha relacionado esta molécula con las proteínas que forman la unión del diafragma entre los pies de los podocitos (nefrina, podocina, Zo-1, CD2AP y Neph-1)2.
In multiple experimental models, angiotensin II has been shown to be the cornerstone of renal progression in proteinuric nephropathies due to its role on glomerular haemodynamics (increases resistance of the efferent arteriole), but also for its proinflammatory and profibrotic capacity by stimulating the synthesis of TNFa, Il-6, and cytokines such as MCP-1 and IP-10.1 In recent years, this molecule has also been related to proteins forming the diaphragm junction between the feet of podocytes (nephrin, podocin, Zo-1, CD2AP, and Neph-1).2
Full Text
In multiple experimental models, angiotensin II has been shown to be the cornerstone of renal progression in proteinuric nephropathies due to its role on glomerular haemodynamics (increases resistance of the efferent arteriole), but also for its proinflammatory and profibrotic capacity by stimulating the synthesis of TNFa, Il-6, and cytokines such as MCP-1 and IP-10.1 In recent years, this molecule has also been related to proteins forming the diaphragm junction between the feet of podocytes (nephrin, podocin, Zo-1, CD2AP, and Neph-1).2
In fact, drug treatments inhibiting its synthesis (angiotensin converting enzyme inhibitors, ACEIs) or blocking its action (angiotensin receptor blockers, ARBs) have been shown to slow progression of renal failure in both diabetic3,4,5 and nondiabetic proteinuric nephropathies6 beyond the effect to be expected from the decrease in systemic blood pressure. Despite this, dialysis continues to be a common endings for this group of patients.
Further knowledge of RAAS blockade has been achieved in recent years. In addition, new drug classes capable of acting in other limiting points of its cascade (renin inhibitors) and with an activity possibly synergistic to already known drugs will be marketed in the near future. This opens up new therapeutic doors that will allow us to optimise their use and achieve what has been called partial or complete remission of these conditions. While we are still far away from these ambitious objectives, some measures that may achieve objectives beyond those expected after the simple prescription of a drug blocking the renin-angiotensin system may currently be considered.
EFFICACY OF RAAS BLOCKADE IN ADVANCED RENAL FAILURE
Treatment with ACEIs and ARBs is underused in patients with proteinuric nephropathy when the glomerular filtration
rate (GFR) is below 30-20 mL/min/1.73m2 because it is thought to have little therapeutic benefit and potential associated side effects, mainly hyperkalemia.
The REIN study7 showed a renoprotective effect of ramipril even in patients with the lowest GFRs (11-33
mL/min/1.73m2). A clinical trial enrolling patients with advanced chronic proteinuric nephropathy (Cr 3.1-5mg/dL; proteinuria > 0.3 g/24 hours) was recently reported.8 In this study, use of benazepril reduced the risk of reaching the combined endpoint proposed (creatinine doubling, dialysis, or death) by 43% as compared to the group treated with antihypertensive drugs other than RAAS inhibitors (mean follow-up time, 3.4 years). Urinary protein excretion was also reduced (50% vs 20%, p < 0.001). Hyperkalemia (K > 6 mEq/l) occurred in 11 patients (11%), 8 of which were treated with dietary measures, potassiumlosing diuretics, and improving acidbase balance. The remaining three patients discontinued the study for this reason. Mean potassium levels were higher in the benazepril-treated
group as compared to the placebo group, but mean differences did not exceed 0.5 mEq/L. No differences were found in mean haemoglobin values or doses of human recombinant erythropoietin.
OPTIMAL NEPHROPROTECTIVE DOSES
Most clinical trials assessing renal progression have used the ACEI and ARB doses recommended in the respective
labels and representing the optimal doses for blood pressure control, though they are possibly below the optimal nephroprotective doses. Forclaz et al9 noted that the usual dose of telmisartan (80 mg/day) achieved blockade
of only 40% of AT1 receptors. The proportion increased to 57% when the dose was doubled.
In the IRMA4 study, the renoprotective effect of irbesartan was dosedependent, but no optimal dose was established. The same authors assessed whether supratherapeutic doses achieved a stronger reduction of albuminuria as compared to the standard dose.10 Thus, 52 patients with type 2 diabetes mellitus and microalbuminuria were sequentially treated with irbesartan 300, 600, and 900 mg/day. All doses were able to reduce microalbuminuria. Mean reductions were 52% (95% CI 46% to 57%), 49% (95% CI 43% to 54%), and 59% (95% CI 54% to 63%) (p < 0.01) respectively. The greatest reduction in microalbuminuria with maximum irbesartan doses was achieved precisely in those patients showing the lowest decrease in albuminuria with the initial dose of 300 mg/day. In another clinical trial,11 high telmisartan doses (80 mg every 12 hours) achieved a significantly stronger decrease in proteinuria as compared to standard doses and reduced loss of estimated GFR
when compared to a 80 mg/24 hour regimen in patients with biopsied nondiabetic proteinuric nephropathy. There
were no differences in blood pressure control during follow-up.
The ROAD study,12 comparing standard doses of an ACEI (benazepril 10 mg/day) and an ARB (losartan 50mg/day) to individualised optimal antiproteinuric doses, was recently published. Patients were treated with increasing doses of benazepril (10, 20, 40 mg/day) and losartan (50, 100, 200 mg/day). Optimal dose was defined as the dose that achieved a greater decrease in proteinuria without increasing serum creatinine by > 30% or SBP to < 120 mm Hg despite discontinuation of all other antihypertensive medication. Mean optimal dose was 20 mg/day for benazepril (range 10-40 mg/day) and 100 mg/day for losartan (range 50-200 mg/day). In both drug classes, optimal doses significantly decreased progression of renal disease as compared to conventional doses, even after adjusting for BP, proteinuria, and baseline GFR. No differences were seen between ACEIs and ARBs at standard or optimal doses.
These results show us of the significant predictive value of proteinuria and its response to treatment for evolution of these patients, but leave unresolved the question as to whether higher than antiproteinuric doses provide any additional nephroprotective benefit.
COMBINED TREATMENT
There are alternative pathways not requiring the participation of renin and ACE for angiotensin II synthesis. Thus,
synthesis of angiotensin II and aldosterone may occur even under treatment with ACEIs; this is the so-called
«escape phenomenon». Approximately 40% of angiotensin synthesis in the kidney occurs through pathways independent from ACE.13 Experimental studies suggest that chymase or cathepsin G may be related.
Blockade of angiotensin II binding to AT1 receptors inhibits most actions of this molecule, including aldosterone
secretion, vasoconstriction, Na and water absorption, and profibrotic and proinflammatory effects, and on the other hand overstimulates expression of actions related to the AT2 receptor, such as vasodilation. However, recent
studies attribute to AT2 receptors an active role in CKD progression. In a renal damage model (subtotal nephrectomy), AT2 blockade reduced proteinuria, nephrin and osteopontin expression, and monocyte-macrocellular
infíltrate to a extent similar to valsartan. 14 Subsequent studies have confirmed that only blockade of both receptors or ACEIs effectively abort the inflammatory cascade triggered by angiotensin II.15
Combination of both drugs would therefore provide a more effective blockade of RAAS and would add the particular benefits of each of them. ACEIs reduce bradykinin degradation. Kinins are known to significantly contribute to the BP decrease attributed to ACEIs. Studies with the bradykinin B2 receptor antagonist in humans revealed that up to 30%-50% of the BP decrease seen after a single dose of ACEIs is mediated by these molecules.16 Increased kinin levels also promote some of the undesirable effects of ACEIs, such as cough, angioneurotic oedema¿
From the clinical viewpoint, the combination of both drugs has also shown more nephroprotective capacity than monotherapy. In the COOPERATE study17 conducted in patients with non-diabetic proteinuric nephropathy (n = 263), only 11% of patients treated with losartan (100 mg/day) plus trandolapril (3 mg/day) doubled their creatinine levels or reached stage 5 CKD after three years of treatment, as compared to 23% of patients treated with monotherapy at the same doses. However, one may wonder whether the benefit seen resulted from the synergistic effect of the combination or use of a higher drug dose. In the Luño et al study,18 monotherapy (lisinopril 40 mg/day, candesartan 32 mg/day) was compared to combined treatment at half the doses (lisinopril+ candesartan 20 + 16 mg/day) in patients with glomerular nephropathies. At six months of follow-up, this latter option achieved a decrease in proteinuria significantly greater than any monotherapy.
There is less evidence available in diabetic nephropathies. The CALM study19 included 199 patients with incipient
nephropathy who were randomized to treatment with lisinopril (20 mg/day) or candersartan (16 mg/day) for 12 weeks. One third of patients were subsequently treated with the combination at the same dose for an additional 12 weeks, while the other two thirds remained on monotherapy. In the first treatment cycle, microalbuminuria reduction was 30% (95% CI 15% to 42%) and 46% (95% CI 35% to 56%) for candesartan and lisinopril respectively. After 24 weeks, the combination reduced microalbuminuria by 50% (95% CI 36% to 61%), i.e. an additional 34% (95% 3% to 55%) as compared to candesartan alone and an additional 18% (95% CI 20 to 44% ) as compared to lisinopril alone.
A systematic review showing that combination treatment is safe and achieves a greater reduction in urinary protein excretion than monotherapy has recently been published. A mean additional decrease of 440 mg/day (95% CI 289 to 591 mg/day) over monotherapy was estimated. In diabetic patients, the combination achieved a smaller decrease (210 mg/day, 95% CI 84 to 336 mg/day) than in patients with nondiabetic proteinuric nephropathies (582
mg/day, 95% CI 371 to 793 mg/day).20 As regarding, the combination resulted in a statistically significant but clinically non-relevant increase in kalemia (mean increase 0.11 mEq/L, 95% CI 0.05 to 0.17 mEq/L).
In the ONTARGET study21 (n = 25,620), conducted on a somewhat different population from the one considered
here (patients at high vascular risk with preserved kidney function [mean creatinine levels 1.2 mg/dL] and only 13% with albuminuria), combination therapy achieved lower BP values than monotherapy (2.4/1.4 mm Hg), but did
not reduce cardiovascular mortality, nor kidney disease progression. By contrast, higher rates of hyperkalemia (p <
0.001), symptomatic hypotension, and patient discontinuation for kidney function impairment (RR 1.58, p < 0.001)
were reported in the study. It would be very interesting to have data from the substudy on patients with proteinuric
renal disease.
OTHER POSSIBLE COMBINATIONS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
Mineralocorticoid receptor antagonists
Diuretics had not been attributed any nephroprotective effect beyond that associated to blood pressure reduction.
In recent years, the role of aldosterone in progression of kidney disease has started to be discussed.22 Aldosterone
has been shown to induce inflammation endothelial dysfunction, glomerular sclerosis, and tubular damage mediated
by inhibition of expression of the plasminogen activator, TGb stimulation, and upregulation of angiotensin II
receptors in different experimental models.23
In clinical trials, association of a mineralocorticoid inhibitor to an ACEI or ARB has achieved an additional reduction of proteinuria.24 Thus, in a study, 268 patients with early type 2 diabetic nephropathy who were already being treated with enalapril were randomised to placebo, eplerenone 50 mg/day, or eplerenone 100 mg/day for 12 weeks.25 Treatment with eplerenone, but not with placebo, reduced albuminuria as compared to baseline. At 12
weeks of treatment, reductions were 7.4% in the placebo group, 41% in the eplerenone 50 mg/day group, and 48%
in the eplerenone 100 mg/day group. There was no increased incidence of moderate (K > 5.5 mEq/L) or severe (K
> 6 mEq/L) hyperkalemia among the three groups, but all patients included had preserved kidney function (Cockcroft eGFR > 70 mL/min). These results may be physiologically explained by the so-called «escape phenomenon » of aldosterone. Sato et al26 found increased plasma aldosterone levels (< 40%) in type 2 diabetic
patients with early nephropathy after 40 weeks of treatment with an ACEI. More recently, similar results have been confirmed in patients with type 1 diabetes treated with ARBs. The escape phenomenon of aldosterone occurred in
> 40% of patients and was associated with a faster loss of glomerular filtration.27
Another, more controversial issue is whether inhibition of the mineralocorticoid receptor in monotherapy could be
beneficial. Theoretically, the spironolactone antagonist may induce secondary elevation of renin and presumably
also of angiotensin II, as other diuretics. 28 This reaction could exaggerate the harmful effect of this molecule.
Unfortunately, there are not yet long-term studies evaluating the role of these drugs and their possible combinations on renal evolution in patients with different grades of chronic kidney disease.
Renin inhibitors
The possibilities of a new drug class that blocks another limiting step in the RAAS cascade, non-peptide renin inhibitors, have been studied in recent years. Aliskiren has an adequate pharmacological profile, and its administration achieves reductions in plasma renin activity and urinary aldosterone levels for at least 48 hours29 with an antihypertensive potency similar to ARBs.30
Theoretically, these drugs would be an adequate adjunct for other drugs blocking the RAAS. Both ACEIs and ARBs stimulate reactive renin secretion because they break the feedback by which angiotensin II inhibits renin secretion in the kidney. It is known that renin may lead to increased angiotensin II levels by its generation through alternative pathways independent from ACE In fact, the combination of aliskiren and valsartan achieved a significantly greater blood pressure reduction than monotherapy with each of the drugs.31
In animal models of renal damage, renin inhibition combined with other ARBs has given encouraging results.32,33
In a recent study, 599 hypertensive patients with established diabetic nephropathy were treated with losartan at
the maximum recommended nephroprotective dose (100 mg/day) and subsequently randomised to aliskiren (300
mg/day) or placebo. In patients treated with the renin inhibitor, urinary albumin excretion was reduced by an additional 20% (95% CI 9-30, p < 0.0001).34
Triple therapies
The RAAS may currently be blocked with drugs at four different sites. As discussed, pathophysiologically and
clinically almost all possible combinations show synergism in at least the intermediate objectives (urinary protein
excretion), and many of them may possibly show synergism in the final objectives (progression of kidney disease).
We may wonder about the superiority of any of them, overall or in particular situations, such as diabetes, obesity¿
A double-blind, controlled clinical trial compared treatment with ACEI monotherapy, ACEIs plus ARBs, ACEIs plus spironolactone, and the combination of all three in 41 patients with proteinuric nephropathy (> 60% diabetic patients). The combination of ACEIs plus spironolactone achieved a 41% greater reduction as compared to ACEI monotherapy, and a 26% greater reduction than that achieved with the combination of ACEIs plus ARBs after 3 months of treatment. Triple therapy did not achieve a greater decrease than seen with the combination of ACEIs
plus spironolactone. Similar results were achieved at 6 months and were independent from blood pressure control.35
CONCLUSIONS
The multiple clinical trials reported in recent years have allowed us to determine the clinical conditions where drugs blocking the RAAS have a renoprotective effect, proteinuric versus non-proteinuric nephropathies,36 and to establish that a more complete blockade results in a greater slowing of renal progression. It is not clear, however,
what therapeutic regimen achieves this objective. Several approaches have been suggested for this purpose,
including high-dose monotherapy and different combinations, but there is still no adequate evidence to recommend
any of them over the rest. It is highly possible that proteinuria is an early intermediate marker of an extraordinary
prognostic value, so that the optimal dose is that achieving a maximum reduction in proteinuria, but we also do not know whether higher doses provide any additional benefit or only result in side effects.
Further clinical trials along these lines, but with more ambitious objectives and including patients with different grades of kidney disease that would help us select the adequate combination therapy in terms of efficacy, but also in terms of safety and tolerability in each condition, are undoubtedly required.
In fact, drug treatments inhibiting its synthesis (angiotensin converting enzyme inhibitors, ACEIs) or blocking its action (angiotensin receptor blockers, ARBs) have been shown to slow progression of renal failure in both diabetic3,4,5 and nondiabetic proteinuric nephropathies6 beyond the effect to be expected from the decrease in systemic blood pressure. Despite this, dialysis continues to be a common endings for this group of patients.
Further knowledge of RAAS blockade has been achieved in recent years. In addition, new drug classes capable of acting in other limiting points of its cascade (renin inhibitors) and with an activity possibly synergistic to already known drugs will be marketed in the near future. This opens up new therapeutic doors that will allow us to optimise their use and achieve what has been called partial or complete remission of these conditions. While we are still far away from these ambitious objectives, some measures that may achieve objectives beyond those expected after the simple prescription of a drug blocking the renin-angiotensin system may currently be considered.
EFFICACY OF RAAS BLOCKADE IN ADVANCED RENAL FAILURE
Treatment with ACEIs and ARBs is underused in patients with proteinuric nephropathy when the glomerular filtration
rate (GFR) is below 30-20 mL/min/1.73m2 because it is thought to have little therapeutic benefit and potential associated side effects, mainly hyperkalemia.
The REIN study7 showed a renoprotective effect of ramipril even in patients with the lowest GFRs (11-33
mL/min/1.73m2). A clinical trial enrolling patients with advanced chronic proteinuric nephropathy (Cr 3.1-5mg/dL; proteinuria > 0.3 g/24 hours) was recently reported.8 In this study, use of benazepril reduced the risk of reaching the combined endpoint proposed (creatinine doubling, dialysis, or death) by 43% as compared to the group treated with antihypertensive drugs other than RAAS inhibitors (mean follow-up time, 3.4 years). Urinary protein excretion was also reduced (50% vs 20%, p < 0.001). Hyperkalemia (K > 6 mEq/l) occurred in 11 patients (11%), 8 of which were treated with dietary measures, potassiumlosing diuretics, and improving acidbase balance. The remaining three patients discontinued the study for this reason. Mean potassium levels were higher in the benazepril-treated
group as compared to the placebo group, but mean differences did not exceed 0.5 mEq/L. No differences were found in mean haemoglobin values or doses of human recombinant erythropoietin.
OPTIMAL NEPHROPROTECTIVE DOSES
Most clinical trials assessing renal progression have used the ACEI and ARB doses recommended in the respective
labels and representing the optimal doses for blood pressure control, though they are possibly below the optimal nephroprotective doses. Forclaz et al9 noted that the usual dose of telmisartan (80 mg/day) achieved blockade
of only 40% of AT1 receptors. The proportion increased to 57% when the dose was doubled.
In the IRMA4 study, the renoprotective effect of irbesartan was dosedependent, but no optimal dose was established. The same authors assessed whether supratherapeutic doses achieved a stronger reduction of albuminuria as compared to the standard dose.10 Thus, 52 patients with type 2 diabetes mellitus and microalbuminuria were sequentially treated with irbesartan 300, 600, and 900 mg/day. All doses were able to reduce microalbuminuria. Mean reductions were 52% (95% CI 46% to 57%), 49% (95% CI 43% to 54%), and 59% (95% CI 54% to 63%) (p < 0.01) respectively. The greatest reduction in microalbuminuria with maximum irbesartan doses was achieved precisely in those patients showing the lowest decrease in albuminuria with the initial dose of 300 mg/day. In another clinical trial,11 high telmisartan doses (80 mg every 12 hours) achieved a significantly stronger decrease in proteinuria as compared to standard doses and reduced loss of estimated GFR
when compared to a 80 mg/24 hour regimen in patients with biopsied nondiabetic proteinuric nephropathy. There
were no differences in blood pressure control during follow-up.
The ROAD study,12 comparing standard doses of an ACEI (benazepril 10 mg/day) and an ARB (losartan 50mg/day) to individualised optimal antiproteinuric doses, was recently published. Patients were treated with increasing doses of benazepril (10, 20, 40 mg/day) and losartan (50, 100, 200 mg/day). Optimal dose was defined as the dose that achieved a greater decrease in proteinuria without increasing serum creatinine by > 30% or SBP to < 120 mm Hg despite discontinuation of all other antihypertensive medication. Mean optimal dose was 20 mg/day for benazepril (range 10-40 mg/day) and 100 mg/day for losartan (range 50-200 mg/day). In both drug classes, optimal doses significantly decreased progression of renal disease as compared to conventional doses, even after adjusting for BP, proteinuria, and baseline GFR. No differences were seen between ACEIs and ARBs at standard or optimal doses.
These results show us of the significant predictive value of proteinuria and its response to treatment for evolution of these patients, but leave unresolved the question as to whether higher than antiproteinuric doses provide any additional nephroprotective benefit.
COMBINED TREATMENT
There are alternative pathways not requiring the participation of renin and ACE for angiotensin II synthesis. Thus,
synthesis of angiotensin II and aldosterone may occur even under treatment with ACEIs; this is the so-called
«escape phenomenon». Approximately 40% of angiotensin synthesis in the kidney occurs through pathways independent from ACE.13 Experimental studies suggest that chymase or cathepsin G may be related.
Blockade of angiotensin II binding to AT1 receptors inhibits most actions of this molecule, including aldosterone
secretion, vasoconstriction, Na and water absorption, and profibrotic and proinflammatory effects, and on the other hand overstimulates expression of actions related to the AT2 receptor, such as vasodilation. However, recent
studies attribute to AT2 receptors an active role in CKD progression. In a renal damage model (subtotal nephrectomy), AT2 blockade reduced proteinuria, nephrin and osteopontin expression, and monocyte-macrocellular
infíltrate to a extent similar to valsartan. 14 Subsequent studies have confirmed that only blockade of both receptors or ACEIs effectively abort the inflammatory cascade triggered by angiotensin II.15
Combination of both drugs would therefore provide a more effective blockade of RAAS and would add the particular benefits of each of them. ACEIs reduce bradykinin degradation. Kinins are known to significantly contribute to the BP decrease attributed to ACEIs. Studies with the bradykinin B2 receptor antagonist in humans revealed that up to 30%-50% of the BP decrease seen after a single dose of ACEIs is mediated by these molecules.16 Increased kinin levels also promote some of the undesirable effects of ACEIs, such as cough, angioneurotic oedema¿
From the clinical viewpoint, the combination of both drugs has also shown more nephroprotective capacity than monotherapy. In the COOPERATE study17 conducted in patients with non-diabetic proteinuric nephropathy (n = 263), only 11% of patients treated with losartan (100 mg/day) plus trandolapril (3 mg/day) doubled their creatinine levels or reached stage 5 CKD after three years of treatment, as compared to 23% of patients treated with monotherapy at the same doses. However, one may wonder whether the benefit seen resulted from the synergistic effect of the combination or use of a higher drug dose. In the Luño et al study,18 monotherapy (lisinopril 40 mg/day, candesartan 32 mg/day) was compared to combined treatment at half the doses (lisinopril+ candesartan 20 + 16 mg/day) in patients with glomerular nephropathies. At six months of follow-up, this latter option achieved a decrease in proteinuria significantly greater than any monotherapy.
There is less evidence available in diabetic nephropathies. The CALM study19 included 199 patients with incipient
nephropathy who were randomized to treatment with lisinopril (20 mg/day) or candersartan (16 mg/day) for 12 weeks. One third of patients were subsequently treated with the combination at the same dose for an additional 12 weeks, while the other two thirds remained on monotherapy. In the first treatment cycle, microalbuminuria reduction was 30% (95% CI 15% to 42%) and 46% (95% CI 35% to 56%) for candesartan and lisinopril respectively. After 24 weeks, the combination reduced microalbuminuria by 50% (95% CI 36% to 61%), i.e. an additional 34% (95% 3% to 55%) as compared to candesartan alone and an additional 18% (95% CI 20 to 44% ) as compared to lisinopril alone.
A systematic review showing that combination treatment is safe and achieves a greater reduction in urinary protein excretion than monotherapy has recently been published. A mean additional decrease of 440 mg/day (95% CI 289 to 591 mg/day) over monotherapy was estimated. In diabetic patients, the combination achieved a smaller decrease (210 mg/day, 95% CI 84 to 336 mg/day) than in patients with nondiabetic proteinuric nephropathies (582
mg/day, 95% CI 371 to 793 mg/day).20 As regarding, the combination resulted in a statistically significant but clinically non-relevant increase in kalemia (mean increase 0.11 mEq/L, 95% CI 0.05 to 0.17 mEq/L).
In the ONTARGET study21 (n = 25,620), conducted on a somewhat different population from the one considered
here (patients at high vascular risk with preserved kidney function [mean creatinine levels 1.2 mg/dL] and only 13% with albuminuria), combination therapy achieved lower BP values than monotherapy (2.4/1.4 mm Hg), but did
not reduce cardiovascular mortality, nor kidney disease progression. By contrast, higher rates of hyperkalemia (p <
0.001), symptomatic hypotension, and patient discontinuation for kidney function impairment (RR 1.58, p < 0.001)
were reported in the study. It would be very interesting to have data from the substudy on patients with proteinuric
renal disease.
OTHER POSSIBLE COMBINATIONS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
Mineralocorticoid receptor antagonists
Diuretics had not been attributed any nephroprotective effect beyond that associated to blood pressure reduction.
In recent years, the role of aldosterone in progression of kidney disease has started to be discussed.22 Aldosterone
has been shown to induce inflammation endothelial dysfunction, glomerular sclerosis, and tubular damage mediated
by inhibition of expression of the plasminogen activator, TGb stimulation, and upregulation of angiotensin II
receptors in different experimental models.23
In clinical trials, association of a mineralocorticoid inhibitor to an ACEI or ARB has achieved an additional reduction of proteinuria.24 Thus, in a study, 268 patients with early type 2 diabetic nephropathy who were already being treated with enalapril were randomised to placebo, eplerenone 50 mg/day, or eplerenone 100 mg/day for 12 weeks.25 Treatment with eplerenone, but not with placebo, reduced albuminuria as compared to baseline. At 12
weeks of treatment, reductions were 7.4% in the placebo group, 41% in the eplerenone 50 mg/day group, and 48%
in the eplerenone 100 mg/day group. There was no increased incidence of moderate (K > 5.5 mEq/L) or severe (K
> 6 mEq/L) hyperkalemia among the three groups, but all patients included had preserved kidney function (Cockcroft eGFR > 70 mL/min). These results may be physiologically explained by the so-called «escape phenomenon » of aldosterone. Sato et al26 found increased plasma aldosterone levels (< 40%) in type 2 diabetic
patients with early nephropathy after 40 weeks of treatment with an ACEI. More recently, similar results have been confirmed in patients with type 1 diabetes treated with ARBs. The escape phenomenon of aldosterone occurred in
> 40% of patients and was associated with a faster loss of glomerular filtration.27
Another, more controversial issue is whether inhibition of the mineralocorticoid receptor in monotherapy could be
beneficial. Theoretically, the spironolactone antagonist may induce secondary elevation of renin and presumably
also of angiotensin II, as other diuretics. 28 This reaction could exaggerate the harmful effect of this molecule.
Unfortunately, there are not yet long-term studies evaluating the role of these drugs and their possible combinations on renal evolution in patients with different grades of chronic kidney disease.
Renin inhibitors
The possibilities of a new drug class that blocks another limiting step in the RAAS cascade, non-peptide renin inhibitors, have been studied in recent years. Aliskiren has an adequate pharmacological profile, and its administration achieves reductions in plasma renin activity and urinary aldosterone levels for at least 48 hours29 with an antihypertensive potency similar to ARBs.30
Theoretically, these drugs would be an adequate adjunct for other drugs blocking the RAAS. Both ACEIs and ARBs stimulate reactive renin secretion because they break the feedback by which angiotensin II inhibits renin secretion in the kidney. It is known that renin may lead to increased angiotensin II levels by its generation through alternative pathways independent from ACE In fact, the combination of aliskiren and valsartan achieved a significantly greater blood pressure reduction than monotherapy with each of the drugs.31
In animal models of renal damage, renin inhibition combined with other ARBs has given encouraging results.32,33
In a recent study, 599 hypertensive patients with established diabetic nephropathy were treated with losartan at
the maximum recommended nephroprotective dose (100 mg/day) and subsequently randomised to aliskiren (300
mg/day) or placebo. In patients treated with the renin inhibitor, urinary albumin excretion was reduced by an additional 20% (95% CI 9-30, p < 0.0001).34
Triple therapies
The RAAS may currently be blocked with drugs at four different sites. As discussed, pathophysiologically and
clinically almost all possible combinations show synergism in at least the intermediate objectives (urinary protein
excretion), and many of them may possibly show synergism in the final objectives (progression of kidney disease).
We may wonder about the superiority of any of them, overall or in particular situations, such as diabetes, obesity¿
A double-blind, controlled clinical trial compared treatment with ACEI monotherapy, ACEIs plus ARBs, ACEIs plus spironolactone, and the combination of all three in 41 patients with proteinuric nephropathy (> 60% diabetic patients). The combination of ACEIs plus spironolactone achieved a 41% greater reduction as compared to ACEI monotherapy, and a 26% greater reduction than that achieved with the combination of ACEIs plus ARBs after 3 months of treatment. Triple therapy did not achieve a greater decrease than seen with the combination of ACEIs
plus spironolactone. Similar results were achieved at 6 months and were independent from blood pressure control.35
CONCLUSIONS
The multiple clinical trials reported in recent years have allowed us to determine the clinical conditions where drugs blocking the RAAS have a renoprotective effect, proteinuric versus non-proteinuric nephropathies,36 and to establish that a more complete blockade results in a greater slowing of renal progression. It is not clear, however,
what therapeutic regimen achieves this objective. Several approaches have been suggested for this purpose,
including high-dose monotherapy and different combinations, but there is still no adequate evidence to recommend
any of them over the rest. It is highly possible that proteinuria is an early intermediate marker of an extraordinary
prognostic value, so that the optimal dose is that achieving a maximum reduction in proteinuria, but we also do not know whether higher doses provide any additional benefit or only result in side effects.
Further clinical trials along these lines, but with more ambitious objectives and including patients with different grades of kidney disease that would help us select the adequate combination therapy in terms of efficacy, but also in terms of safety and tolerability in each condition, are undoubtedly required.
Bibliography
[1]
1 Ruiz-Ortega M, Bustos C. Hernández Presa MA, Lorenzo O, Plaja JJ, Egido J. Angiotensin II participates in mononuvlear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte cheattractant protein-1 synthesis. J Immunol 1998;161:430-439. [Pubmed]
[2]
2 Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997;99:342-348. [Pubmed]
[3]
3 Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 2001;345: 861¿869
[4]
4 Parving HH, Lehnert H, Brochener-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartab on the development of diabetic nephropathy in patients sith type 2 diabetes. N Engl J Med 2001;345:851-860. [Pubmed]
[5]
5 Lewis E, Hunsicker L. Clarke W, Berl T, Pohl M, Lewis J, Ritz E, Atkins RC, Rohde R, Raz I. For the collaborate study group. N Engl J Med 2001;345:851-860. [Pubmed]
[6]
6 The GINSEN Group. Randomised placebo controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non diabetic nephropathy. Lancet 1997;349:1857-1863. [Pubmed]
[7]
7 Ruggenenti P, Perna A, Remuzzi G, ACE inhibitors to prevent end stage renal disease. When to start and why possibly never to stop: A post hoc analysis of the REIN trial results. J Am Soc Nephrol 2001;12:2832 [Pubmed]
[8]
8 Hou FF, Zhang Z, Zhang GH, Xie C, Chen PY, Zhang Wr, jian JP, Liang M, Wang GB, Liu ZR, Geng RW Efficacy and safety benazepril for advance chronic renal insufficiency.. N Engl J Med 2006; 12:131-140
[9]
9 Forclaz A, Maillard M, Nussberg J, Brunner HR, Murnier M. Angiotensin II receptor blockade. Is there truly a Benefit of adding an ACE Inhibitor? Hypertension 2003;41:31-36.
[10]
10 Rossing K, Schjoedt KJ, Jensen Br, Boomsma F, Parving HH. Enhaced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005;68:1190-1198. [Pubmed]
[11]
11 Aranda P, Segura J, Ruilope L, Aranda FJ, Frutos A, López V, López Novales E. Long-term renoprotective effects of standard versus high doses of Telmisartan Hypertensive nondiabetic Nephropathies. Am J Kidney Dis 2005; 46:1074-1079. [Pubmed]
[12]
12 Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, Guo ZJ, Jiang JP. Renoprotection of Optimal antiproteinuric doses (ROAD) Study : A randomizedControlle Study of Benazepril and Losartan in Chronic Renal Insufficiency. J Am Soc Nephrol 2007;18:1889-1898 [Pubmed]
[13]
13 Hollenberg NK. Pharmacologic interruption of the renin-angiotensin system and the kidney: differential responses to angiortensin converting enzyme and renin inhibition. J Am Soc Nephrol 1999;10 (supl):S239-S242 [Pubmed]
[14]
14 Cao Z, Bonet F, Candido R, Nesteroff SP, Burns WC, Kawachi H, Shimizu F, Carey RM, Gasparo M, Cooper ME. Angiotensin Type 2 receptor antagonism confers Renal Protection in a Rat model of Progressive Renal Injury. J Am Soc Nephrol 2002;13:1773-1787. [Pubmed]
[15]
15 Esteban V, Lorenzo O, Ruiperez M, Suzuki Y, Mezzano S, Blanco J, Kretzoles M, Sugaya T, Egido J, Ruiz Ortega M. Angiotensin, via AT1 and AT2 receptor and NF-KappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 2004;15:1514-1529. [Pubmed]
[16]
16 Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin receptor blockade on the response to angiotensin converting enzyme inhibitor in normotenisve and hypertensive subjects N Engl J Med 1998:339:1285-1295.
[17]
17 Nakao N, Yoshimura A, Morita H, Takda M, Rayano T, Ideura T.Combination treatment of angiotensin II receptor blocker and angiotensin converting enzyme inhibitors in non diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-124. [Pubmed]
[18]
18 Luño J, Barrio V, Goicoechea M, González C, Garcia de Vinuesa S, Gómez F, Bernis C, Espinosa M, Ahijado E, Gomez J, Escalada P. Effects of dual blockade og the rennin-angiotensin system in primary proteinuric nephropathies. Kidney Int Suppl 2002;82;S47-S52. [Pubmed]
[19]
19 Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME for the study group. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulindependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-1444. [Pubmed]
[20]
20 MacKinnon M, Shurraw S, Akbari A, Knoll G, Jaffey J, Clark H. Combination therapy with an Angiotensin Receptor Blocker and an ACE inhibitor in Proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis 2006;48:8-20 [Pubmed]
[21]
21 Telmisartan, ramipril, or both in patients at high risk for vascular events. The ONTARGET investigators. N Engl J Med 2008;358:1547-1559. [Pubmed]
[22]
22 Epstein M. Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications. Am J Kidney Dis 2001;37:677-688 [Pubmed]
[23]
23 Epstein M. Aldosterone and the hypertensive kidney : its emerging role as a mediator or progressive renal dysfunction: A paradigm shift. J Hypertensions 2001;19:829-842.
[24]
24 Van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D. Spironolactone in type 2 diabetic nephropathy : effect on proteinuria, blood pressure and renal function. J Hypertens 2006;24:2285-2292 [Pubmed]
[25]
25 Epstein M. William Gh, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B. Selective aldosterone blockade with eplerenona reduces albuminuria in patients with type 2 diabetes Clin J Am Soc Nephrol 2006:21;940-951.
[26]
26 Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64-68. [Pubmed]
[27]
27 Schojoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH Aldosterone escape during blockade of the renin angiotensin aldosterona system in diabetic nephropathy is associate with enhanced decline in glomerular filtration rate. Diabetología 2004;47:1936-1939. [Pubmed]
[28]
28 Hesse B, Nielsen I, Lund-Jacobsen H. The early effects of intravenous furosemide on central haemodynamics venous tone and plasma renin activity. Clin Sci Mol Med 1975;49;551-555. [Pubmed]
[29]
29 Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S, Camisasca RP: Pharmacologic demonstration of the synergistic effects of a combination of the rennin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol2004; 15: 3126¿3133 [Pubmed]
[30]
30 Stanton A, Jensen C, Nussberger J, O¿Brien E: Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137¿1143.
[31]
31 Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221-229 [Pubmed]
[32]
32 Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Jan Danser AH, Luft FC, Muller DN: Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hipertensión 2005: 46: 569¿576.
[33]
33 Shagdarsuren E, Wellner M, Braesen JH, Park JK, Fiebeler A, Henke N, Dechend R, Gratze P, Luft FC, Muller DN: Complement activation in angiotensin II-induced organ damage. Circ Res 2005; 97: 716¿724.
[34]
34 Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg N, Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008:358:2433-2446. [Pubmed]
[35]
35 Chrysostomou A, Pedagogos E, MacGregor L, Becker G. Double-Blind, placebo-controlled study on the effect of the aldosterone Receptor antagonist Spironolactone in Patients who have persistent proteinuria and are on long term angiotensin-converting enzyme inhibito therapy with ow without an angiotensins II receptor blocker Clin J Am Soc Nephrol 2006;1:256-262. [Pubmed]
[36]
36 Rahman M, Pressel S, Davis B, Nwachuku C, Wright J, Whelton P, Barzilay J, Batuman V, Eckfedt J, Farber M, Hernriquez M, Kopyt N, Louis GT, Saklayen M, stanford C, Walworth C, Ward H, Wiegmann T. Renal outcomes in high risk hypertensive patients treated with a angiotensin converting enzyme inhibitor or a calcium channel blocker vs diuretic. Arch Inter Med 2005;165:936-946.
